Teva Announces Launch Of The First And Only Generic Version Of Sandostatin LAR Depot, In The U.S.
Teva Announces Launch Of The First And Only Generic Version Of Sandostatin LAR Depot, In The U.S.
Teva宣布在美国推出第一款也是唯一的Sandostatin LAR Depot仿制药版本。
-
This first-to-market launch showcases Teva's proven strengths in complex generic formulations and enhances Teva's strategic goal of sustaining a generic powerhouse.
- Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome.
- 这次首次上市展示了梯瓦在复杂通用配方方面的实力，增强了梯瓦持续成为通用药强大力量的战略目标。
- 奥曲唑酸肽可用于注射悬液，适用于治疗肢端肥大症和类癌综合症所致的严重腹泻。
PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin1 LAR Depot, in the United States.
纽交所及TASE证券代码：TEVA）的美国附属公司梯瓦制药于2024年10月01日宣布，在美国推出了Sandostatin1 LAR Depot的首个唯一通用版本。
Octreotide acetate for injectable suspension (the generic version of Sandostatin LAR Depot) is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome. Please see the below for more information.
奥曲唑酸肽可用于注射悬液（Sandostatin LAR Depot的通用版本），适用于治疗肢端肥大症和类癌综合症所致的严重腹泻。更多信息请见下文。